LDL cholesterol (LDL-C): ranges, results and what changes it

The mmol/L boundaries above are exact conversions of the mg/dL cutoffs. Laboratories may display fewer decimals, so classify from the original reported value and unit rather than moving a rounded conversion across a boundary.^{See reference 19}

The table gives widely used adult descriptors, not a diagnosis and not a treatment plan. A value labelled “optimal” by a general table can still be above a clinician-agreed target for someone with established cardiovascular disease, diabetes, chronic kidney disease, familial hypercholesterolaemia or another high-risk context. Children use different categories.^{See reference 1,See reference 2,See reference 8}

Current U.S. guidance uses risk-based goals. Examples include below 100 mg/dL for some borderline- or intermediate-risk primary-prevention decisions, below 70 mg/dL for high-risk primary prevention, and below 55 mg/dL for many people at very high risk after cardiovascular disease. Percentage reduction from baseline also matters.^{See reference 1,See reference 2}

European guidance also uses risk categories but not exactly the same decision pathway. Its retained examples range from below 116 mg/dL in low-risk adults to below 55 mg/dL plus at least a 50% reduction in very-high-risk adults. These are jurisdiction-specific clinical goals, not a worldwide self-treatment chart.^{See reference 3}

Cholesterol cannot travel through blood alone, so lipoprotein particles carry it. LDL-C reports the cholesterol mass inside LDL particles. Evidence from genetics, population studies and randomized treatment trials supports LDL particles as a causal contributor to atherosclerotic cardiovascular disease, with risk related to both the concentration and duration of exposure.^{See reference 4,See reference 15}

LDL-C does not directly count particles. Two people can carry similar LDL cholesterol in different numbers of particles. Non-HDL cholesterol and, in selected situations, ApoB can reveal particle-related risk that LDL-C alone may underestimate—especially with high triglycerides, diabetes, metabolic syndrome or a very low treated LDL-C.^{See reference 1,See reference 5}

High LDL-C usually causes no symptoms; a blood test is how it is found.^{See reference 20}

Chest pressure or shortness of breath can be heart-attack warning signs. Sudden facial droop, arm weakness or speech difficulty can be stroke warning signs. Seek emergency help immediately for these symptoms regardless of any LDL result; they are not “symptoms of high LDL.”^{See reference 21,See reference 22}

For LDL cholesterol, multiply mg/dL by 0.02586 to obtain mmol/L, or multiply mmol/L by 38.67 to obtain mg/dL. Round only for display. Triglycerides use a different conversion factor, so a general “blood test converter” can give a dangerously wrong answer.^{See reference 19}

The tools above convert units only. They do not decide a personal target, and a rounded converted value should not be used to move a result across a treatment boundary.^{See reference 1,See reference 19}

Common contributors include inherited differences in LDL clearance, a dietary pattern high in saturated or trans fat, hypothyroidism, kidney disease such as nephrotic syndrome, cholestatic liver disease, pregnancy and certain medicines. More than one factor can apply at the same time.^{See reference 1,See reference 8,See reference 10}

A lean body, regular exercise, low triglycerides or high HDL does not rule out genetically or diet-sensitive high LDL. Conversely, diabetes and insulin resistance may raise ApoB and triglyceride-rich particles even when LDL-C is not dramatically high.^{See reference 1,See reference 5}

Do not stop a medicine or make an extreme diet change based only on one result. Review the trend, method, thyroid and relevant kidney or liver context, family history, pregnancy status and current medicines with a clinician.^{See reference 1,See reference 9,See reference 10}

A low LDL-C during effective prescribed treatment is usually intentional and is not automatically dangerous. Randomized and genetic evidence has not established cognitive harm from intensive LDL lowering, although people with a history of brain haemorrhage need individual specialist advice.^{See reference 1,See reference 17}

An unexpected LDL-C below about 50 mg/dL (1.3 mmol/L) while untreated can occur with hyperthyroidism, undernutrition, malabsorption, chronic infection or inflammation, some cancers and rare genetic conditions. The value does not diagnose any of them, but context may justify review.^{See reference 11}

Non-HDL-C is total cholesterol minus HDL-C and captures cholesterol across LDL, remnant particles and Lp(a). ApoB approximates the number of atherogenic particles because each usually carries one ApoB molecule. Lp(a) is a largely inherited particle that requires its own test.^{See reference 1,See reference 5}

When LDL-C and ApoB disagree, do not compare their raw numbers as though they share a unit or cutoff. Discordance means they occupy different population or risk positions. Current U.S. guidance particularly considers ApoB after LDL-C or non-HDL-C goals are reached, especially with ASCVD, cardiovascular-kidney-metabolic syndrome, type 2 diabetes, triglycerides at or above 150 mg/dL, or achieved LDL-C below 70 mg/dL.^{See reference 1}

Particle-size labels do not make LDL harmless. All LDL particles can enter the artery wall. LDL-P, small LDL, oxidized LDL and LDL/HDL ratios are distinct catalog tests and should not be silently merged into an LDL-C interpretation.^{See reference 4,See reference 5}

Across statin trials, lowering LDL-C by 1 mmol/L (about 38.7 mg/dL) reduced major vascular events by roughly one fifth in relative terms. That is relative risk reduction: the absolute benefit for one person depends on starting risk, age, other conditions and how long treatment continues.^{See reference 15}

Lifestyle supports cardiovascular health and remains part of treatment, but it does not reliably normalize severe genetic LDL elevation. Prescribed medicines should not be stopped because a new diet or supplement is being tried.^{See reference 1,See reference 9,See reference 14}

Current U.S. guidance does not recommend dietary supplements as a substitute for evidence-based LDL management. Red yeast rice can contain a compound identical to lovastatin in unpredictable amounts and can share statin-like side effects and drug interactions.^{See reference 1,See reference 18}

General screening intervals depend on age and risk. Current U.S. guidance supports a lipid panel for adults from age 19 and at least every five years when no closer follow-up is needed. Heart disease, diabetes, kidney disease, strong family history or treatment can justify more frequent testing.^{See reference 1,See reference 8}

After starting or changing lipid-lowering treatment, a repeat at about 4–12 weeks can assess response and adherence, followed by roughly every 6–12 months when stable. This is a general framework, not a substitute for the clinician's schedule.^{See reference 1}

Pregnancy raises LDL physiologically. Anyone pregnant or planning pregnancy while taking a lipid medicine should discuss the medicine before changing it; rare very-high-risk cases require specialist decisions rather than a blanket rule.^{See reference 1}